Friday’s General Session included two studies into race as a factor in the incidence, severity, and treatment outcomes of breast cancer.

Fabrice André, MD, PhD, received this year’s AACR Outstanding Investigator Award for Breast Cancer Research for his work helping to establish the concept of using real-time, high-throughput genomic analysis of cancer biopsies to identify potential therapeutic targets.

Lori Wilson, MD, and Charles Perou, PhD, gave keynote presentations during a special session focused on advancing health equity through building trust and improving access to care and clinical trials.

Thursday’s General Session included findings from a study looking at fulvestrant plus palbociclib for HR+ breast cancer and results of a study of pyrotinib plus capecitabine for previously treated HER2+ metastatic breast cancer.

Helen M. Piwnica-Worms, PhD, discussed her journey from basic research to translational trials during the 2021 AACR Distinguished Lectureship in Breast Cancer Research on Thursday.

During a debate this morning, Charlotte Coles, MBChB, PhD, will present the “Pro” argument, and Julia White, MD, will present the “Con” argument on the adoption of a new schedule for whole breast radiotherapy.

Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.

Olufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.

A special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.